243 related articles for article (PubMed ID: 20217126)
41. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.
Chan MW; Chan LW; Tang NL; Lo KW; Tong JH; Chan AW; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
Int J Cancer; 2003 May; 104(5):611-6. PubMed ID: 12594816
[TBL] [Abstract][Full Text] [Related]
42. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of thymosin β4 in the regulation of epithelial-mesenchymal transformation in urothelial carcinoma.
Wang ZY; Zeng FQ; Zhu ZH; Jiang GS; Lv L; Wan F; Dong R; Xiao XY; Xing SA
Urol Oncol; 2012; 30(2):167-76. PubMed ID: 20864366
[TBL] [Abstract][Full Text] [Related]
44. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Urakami S; Honda S; Shirakawa H; Ishibe T
J Clin Pathol; 1996 May; 49(5):395-9. PubMed ID: 8707954
[TBL] [Abstract][Full Text] [Related]
45. Expression of VEGF in urinary bladder transitional cell carcinoma in an Iraqi population subjected to depleted uranium: an immunohistochemical study.
Al-Abbasi DS; Al-Janabi AA; Al-Toriahi KM; Jabor TA; Yasseen AA
Appl Immunohistochem Mol Morphol; 2009 Jul; 17(4):307-11. PubMed ID: 19151604
[TBL] [Abstract][Full Text] [Related]
46. Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.
Lin YL; Liu XQ; Li WP; Sun G; Zhang CT
Int Urol Nephrol; 2012 Feb; 44(1):111-7. PubMed ID: 21516472
[TBL] [Abstract][Full Text] [Related]
47. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
48. Decrease of DNA methyltransferase 1 expression relative to cell proliferation in transitional cell carcinoma.
Kimura F; Seifert HH; Florl AR; Santourlidis S; Steinhoff C; Swiatkowski S; Mahotka C; Gerharz CD; Schulz WA
Int J Cancer; 2003 May; 104(5):568-78. PubMed ID: 12594811
[TBL] [Abstract][Full Text] [Related]
49. Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma.
Shang C; Guo Y; Zhang H; Xue YX
Cancer Chemother Pharmacol; 2016 Mar; 77(3):507-13. PubMed ID: 26781446
[TBL] [Abstract][Full Text] [Related]
50. Down-regulation of Ku 70 and Ku 80 mRNA expression in transitional cell carcinomas of the urinary bladder related to tumor progression.
Korabiowska M; Quentin T; Schlott T; Bauer H; Kunze E
World J Urol; 2004 Dec; 22(6):431-40. PubMed ID: 15551138
[TBL] [Abstract][Full Text] [Related]
51. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
[TBL] [Abstract][Full Text] [Related]
52. Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer.
Sachs MD; Rauen KA; Ramamurthy M; Dodson JL; De Marzo AM; Putzi MJ; Schoenberg MP; Rodriguez R
Urology; 2002 Sep; 60(3):531-6. PubMed ID: 12350512
[TBL] [Abstract][Full Text] [Related]
53. Expression of bcl-2 and bcl-X in bladder cancer.
Kirsh EJ; Baunoch DA; Stadler WM
J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
[TBL] [Abstract][Full Text] [Related]
54. Exon 2 methylation inhibits hepaCAM expression in transitional cell carcinoma of the bladder.
Pan C; Wu X; Luo C; Yang S; Pu J; Wang C; Shen S
Urol Int; 2010; 85(3):347-54. PubMed ID: 20628239
[TBL] [Abstract][Full Text] [Related]
55. Epigenetic inactivation of ST6GAL1 in human bladder cancer.
Antony P; Rose M; Heidenreich A; Knüchel R; Gaisa NT; Dahl E
BMC Cancer; 2014 Dec; 14():901. PubMed ID: 25465919
[TBL] [Abstract][Full Text] [Related]
56. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer.
Christoph F; Kempkensteffen C; Weikert S; Köllermann J; Krause H; Miller K; Schostak M; Schrader M
Br J Cancer; 2006 Dec; 95(12):1701-7. PubMed ID: 17133271
[TBL] [Abstract][Full Text] [Related]
57. Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma.
Guan Y; Song H; Zhang G; Ai X
Oncol Rep; 2014 Aug; 32(2):748-54. PubMed ID: 24890092
[TBL] [Abstract][Full Text] [Related]
58. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder.
Jalali Nadoushan MR; Taheri T; Jouian N; Zaeri F
Urol J; 2007; 4(3):151-4. PubMed ID: 17987577
[TBL] [Abstract][Full Text] [Related]
59. 5-azacytidine inhibits the proliferation of bladder cancer cells via reversal of the aberrant hypermethylation of the hepaCAM gene.
Wang X; Chen E; Yang X; Wang Y; Quan Z; Wu X; Luo C
Oncol Rep; 2016 Mar; 35(3):1375-84. PubMed ID: 26677113
[TBL] [Abstract][Full Text] [Related]
60. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
